Afficher la notice abrégée

Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study

dc.rights.licenseopenen_US
dc.contributor.authorPRETERRE, J.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorVISENTIN, Jonathan
dc.contributor.authorSAINT CRICQ, M.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorKAMINSKI, Hannah
dc.contributor.authorDEL BELLO, A.
dc.contributor.authorPREZELIN-REYDIT, M.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorMERVILLE, Pierre
dc.contributor.authorKAMAR, N.
dc.date.accessioned2022-05-09T10:19:37Z
dc.date.available2022-05-09T10:19:37Z
dc.date.issued2021-03
dc.identifier.issn1399-0012en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140003
dc.description.abstractEnAfter kidney transplantation, withdrawal of calcineurin inhibitors (CNI) and conversion to sirolimus (SRL) may reduce the occurrence of new non-melanoma skin cancer (NMSC). Conversely, a reduced CNI exposure with everolimus (EVR) is an alternative strategy that has not been thoroughly evaluated. We retrospectively compared the occurrence of newly diagnosed NMSCs in two cohorts of kidney transplant recipients (KTR) with at least one NMSC: 35 patients were converted to EVR with reduced CNI exposure (CNI/EVR group), whereas 46 patients were converted to SRL in association with mycophenolic acid (MPA) (SRL/MPA group). Two years after conversion, survival free of new NMSC was similar between the two cohorts (p=.37), with 19 KTR (54.3%) in the CNI/EVR group and 22 (47.8%) in the SRL/MPA group being diagnosed of at least one new NMSC. Half of the KTR from both groups showed adverse events, leading to mTORi discontinuation for 37.1% of KTR in the CNI/EVR group and 21.7% in the SRL/MPA group (p=.09). The incidence of rejections was similar between the two groups. In a retrospective cohort of KTR with at least one post-transplant NMSC, the outcome of the patients converted to a CNI/EVR regimen was not different from those converted to a SRL/MPA regimen.
dc.language.isoENen_US
dc.subject.enEverolimus
dc.subject.enKidney transplantation
dc.subject.enLow-dose CNI
dc.subject.enSecondary prevention
dc.subject.enSkin cancer
dc.title.enComparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/ctr.14207en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed33369772en_US
bordeaux.journalClinical Transplantationen_US
bordeaux.volume35en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03662415
hal.version1
hal.date.transferred2022-05-09T10:19:39Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Transplantation&rft.date=2021-03&rft.volume=35&rft.issue=3&rft.eissn=1399-0012&rft.issn=1399-0012&rft.au=PRETERRE,%20J.&VISENTIN,%20Jonathan&SAINT%20CRICQ,%20M.&KAMINSKI,%20Hannah&DEL%20BELLO,%20A.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée